Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $17.6600 (0.23%) ($17.2900 - $18.0100) on Fri. Jul. 28, 2017. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.25% (three month average) | RSI | 63 | Latest Price | $17.6600(0.23%) | Stocks Behave Similarly | Similar Stock List | Weekly Trend | ADMS advances 3.2% a week on average for past two weeks. | Market Behavior | Normal for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) XBI(25%) IBB(22%) XOP(18%) ARKG(17%) IWC(17%) | Factors Impacting ADMS price | ADMS will decline at least -1.125% in a week (0% probabilities). VIXM(-11%) UUP(-11%) UNG(-9%) BNDX(-7%) TLT(-5%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.125% (StdDev 2.25%) | Hourly BBV | 0 () | Intraday Trend | 0.9% | | | |
|
5 Day Moving Average | $17.98(-1.78%) | 10 Day Moving Average | $17.67(-0.06%) | 20 Day Moving Average | $17.5(0.91%) | To recent high | -4.3% | To recent low | 19.8% | Market Cap | $499m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |